PACE 919 . RCVD AT 1/28/2004 9:49:53 AM [Eastern Standard Time] . SVR:USPTO EFXRF-1/12" ONIS:8729306 . CSID:973 781 8064 " DURATION (mm-ss):02-04

FORM PTO-1449 (REV. 7-65) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO. 4-33182A APPLICATION NO. 09/778,280 APPLICANT MICHAEL WYLLIE FILING DATE

FEBRUARY 7, 2001

Group 1614

Sheet 1 of 1

U.S. PATENT DOCUMENTS DOCUMENT NUMBER DATE NAME CLASS SUBCLASS FILING DATE INTIAL AA AB AC AD AE AF AG AH Αı **A.1** AK AL **FOREIGN PATENT DOCUMENTS** DOCUMENT NUMBER TRANSLATION YES NO CLASS DATE OFFICE SUBCLASS AM AN AO AP AQ OTHER DOCUMENTS (including Author, Title, Date, Pertinent pages, Etc.) Serels, S., and Stein, M. Prospective study comparing hyoscyamine, doxazosin, and combination AR therapy for the treatment of urgency and frequency in women. Neurourological Urodynamics, Vol. 17(1), pp. 31-36, 1998 (Abstract). **AS EXAMINER** DATE CONSIDERED 29 *EXAMINER: 'Gittle' by reference considered, whether or not citation is in conformance with MPEP 609: Draw's line through citation is not in conformance and not considered. (include a copy of this form with the next communication to applicant. *EXAMINER: